QualityStocks would like to highlight
Avant Diagnostics, Inc. (
OTCQB: AVDX), a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
In the company’s news,
Avant Diagnostics, Inc. (OTC: AVDX) is on a mission to maximize its levels of corporate transparency for the benefit of its customers and investors. Late last week, the company took a significant step toward realizing this goal when it unveiled its new website. The new site utilizes a number of design features aimed at making browsing both streamlined and informative for Avant’s current and potential customers and investors.
The site’s investor relations section, in particular, received a considerable upgrade, incorporating helpful features such as immediate posting of press releases and automated posting of SEC filings, XBRL data, Insider Section 16 filings and financial statements. Additionally, the company has incorporated CEO interviews and media coverage, corporate videos and an up-to-date frequently asked questions section in order to more adequately inform visitors about Avant’s latest advances.
“A significant part of Avant’s mission is presenting those interested in the company with the information they want in the quickest and most organized way,” Gregg Linn, president and chief executive officer of Avant, stated in a news release. “We believe our new website advances this goal by presenting our range of services and activities in an attractive and easy-to-access format.”
In the months to come, Avant in strategically positioned to continue the development of its pre-symptomatic ovarian cancer screening test, OvaDx®. Leveraging more than 10 years of research and development and a strong intellectual property portfolio, the company is seeking to reduce the costs associated with ovarian cancer detection while helping medical providers avoid costly late stage disease treatments.
According to data from the American Cancer Society, ovarian cancer ranks fifth in cancer deaths among women, accounting for more fatalities than any other cancer of the female reproduction system. However, early detection can play a major role in improving the survivability of this dangerous disease. According to the National Cancer Institute, ovarian cancer cases discovered in stage I development present patients with a five-year relative survival rate in excess of 92 percent. Despite the benefits of early detection, only about 15 percent of ovarian cancer cases are currently diagnosed at stage one.
Through the development of OvaDx, Avant is seeking to provide a more effective option for detecting early stage ovarian cancer. The microarray-based diagnostic test, which, upon FDA approval, is expected to be offered as an elective test for women with elevated risk of ovarian cancer, has been shown to detect stage IA disease markers with approximately 80 percent sensitivity and 100 percent specificity.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
